Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Business & Finance
Shareholder states intent to vote against $4.40 per share bid to acquire Corixa
July 14th, 2005
MPM BioEquities Adviser, LLC announced that it is voting its 1.1 million shares against the proposed acquisition of Corixa (CRXA) by GlaxoSmithKline (GSK) (GSK). MPM has communicated to Corixa its belief that Corixa shareholders are not receiving a fair value from the proposed acquisition. MPM's own analysis of the acquisition value of Corixa to GSK provides a fair and reasonable value of approximately $6.50. In accepting a significantly lower price, MPM believes that Corixa's board of directors has not fully appreciated either the value of the MPL adjuvant program or the novel TLR4 program. Corixa receives a significant...
Source: Women's Health Weekly (2005-07-14)
|
